Program Description
In men with advanced prostate cancer, disease management has been shaped by androgen-deprivation therapy, which acts by reducing circulating levels of androgen or inhibiting the activity of the androgen receptor. Currently approved anti-androgen therapy is administered orally and has contributed to challenges in toxicity management and ensuring adherence. As they develop treatment pathways, managed care pharmacists need to not only be aware of agents already on the market, but also of emerging therapies and interventions. This program will review the changing landscape of prostate cancer treatment with anti-androgen therapies as well as investigate combination therapy of anti-androgens with PARP inhibitors. The discussion will also address disparities in care, toxicity mitigation strategies, and cost-effectiveness data managed care pharmacists must consider during treatment selection to ensure continued patient access to prostate cancer therapies.
Target audience: Managed care pharmacists, oncology pharmacists
Type of activity: Application
Release date: June 22, 2023
Expiration date: August 22, 2023
Time to complete activity: 1.5 hours
Learner level: Foundational, intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the principles of anti-androgen therapy and the factors that influence the treatment approach in prostate cancer.
- Analyze recent guideline updates and clinical data for the use of anti-androgen therapy in patients with prostate cancer.
- Investigate strategies available to managed care teams to alleviate symptoms and ease toxicities of anti-androgen therapy in patients with prostate cancer.
- Identify approaches to optimize care for patient populations with prostate cancer using overall resource utilization and cost-effectiveness data.
Sara Moran Smith, PharmD, BCOP
Oncology Pharmacy Program Manager
Allina Health
Minneapolis, Minnesota
Sherry L. Vogt, PharmD, BCOP
Clinical Specialist Pharmacist- Oncology
Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-241-L01-P. The activity is available for CE credit through August 22, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Sara Moran Smith, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: G1 Therapeutics
Speaker's Bureau: Karyopharm, Regeneron
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Sherry L. Vogt, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms